Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
复制标题
DOI：
--
复制
发表时间：
1987
期刊：
影响因子：
11.2
通讯作者：
Y. Yeh;J. Tsai;L. Chuang;H. Yeh;J. Tsai;D. Florine;J. Tam
中科院分区：
文献类型：
--
作者：
Y. Yeh;J. Tsai;L. Chuang;H. Yeh;J. Tsai;D. Florine;J. Tam
用合成的大鼠肉瘤转化生长因子及其兔多克隆抗体建立了转化生长因子-α（TGF-α）的放射免疫分析法。采用放射免疫分析法，测定了31例肝细胞癌（HCC）患者、15例疑似HCC患者、4例转移性肝癌患者和33例年龄、性别匹配的健康对照者的尿TGF-α和表皮生长因子（EGF）浓度。我们首次发现，HCC患者的平均TGF-α浓度为21.5 +/- 20.3微克/克肌酐，显著高于健康受试者的4.9 +/- 2.8微克/克肌酐（P <0.001）。HCC患者和对照组的EGF水平无统计学差异（40.9 +/- 29.3 vs 46.2 +/- 16.6微克/克肌酐; P> 0.05）。HCC患者的EGF/TGF-α比值（3.37 ± 4.42）与对照组（15.5 ± 13.0）之间存在显著差异（P <0.001）。在患者中，65%（20/31）的HCC病例和87%（13/15）的可能HCC病例显示TGF-α水平显著升高。我们发现只有16%（31例中的5例）的HCC病例EGF水平升高。EGF的分泌与年龄呈负相关。血清总蛋白浓度和碱性磷酸酶活性与EGF浓度呈正相关（r = 0.522，P <0.01; rt = 0.393，P <0.05）。肝细胞癌患者的肝脏生化功能与TGF-α浓度之间无相关性。我们的研究结果还表明，TGF-α可能是一个有用的补充肿瘤标志物，用于管理具有低甲胎蛋白水平的HCC临床表现的患者。
A radioimmunoassay for transforming growth factor alpha (TGF-alpha) using synthetic rat sarcoma transforming growth factor and its rabbit polyclonal antibody has been developed. Using radioimmunoassays, the urinary TGF-alpha and epidermal growth factor (EGF) concentrations in 31 patients with hepatocellular carcinoma (HCC), 15 probable HCC, four metastatic liver cancer, and 33 age, sex-matched healthy controls were determined. For the first time, we have shown that the average TGF-alpha concentration for HCC patients was 21.5 +/- 20.3 micrograms per g creatinine, significantly higher than that of healthy subjects, 4.9 +/- 2.8 micrograms per g creatinine (P less than 0.001). There was no statistical difference in the level of EGF between HCC patients and controls (40.9 +/- 29.3 versus 46.2 +/- 16.6 micrograms per g creatinine; P greater than 0.05). The ratio of EGF/TGF-alpha between HCC patients (3.37 +/- 4.42) and controls (15.5 +/- 13.0) was significantly different (P less than 0.001). Among patients, 65% (20 of 31) of HCC cases and 87% (13 of 15) of probable HCC cases showed a marked elevation of TGF-alpha levels. We found only 16% (five of 31) of HCC cases with increased EGF level. EGF excretion was inversely age related. Serum total protein concentration and alkaline phosphatase activity were positively correlated to EGF concentration (r = 0.522, P less than 0.01 and rt = 0.393, P less than 0.05, respectively). There was no correlation between biochemical functions of liver and TGF-alpha concentration in HCC patients. Our results also suggested that TGF-alpha may be a useful complementary tumor marker for management of patients with clinical manifestation of HCC who have low alpha-fetoprotein levels.